Sign In
Don’t have an account?
    About CKD
  • The Firialta Patient
  • MOD and MOA
    Trial Design
  • Clinical Efficacy
  • Safety
    Dosing
    Resources
logo_firialta
About CKD
MOD and MOA
Trial Design
  • Primary composite renal endpoint
  • Secondary composite CV endpoint
  • UACR efficacy
Safety
Dosing
Resources
closesearch
Recent Searches
    You Are Now Leaving This Site

    Would you like to leave this site?

    background

     

     

     

     

    One move can change the outcome1

    For your patients with CKD 

    associated with T2D, intervene now to deliver 

    dual cardiorenal risk reduction

    CKD=chronic kidney disease; T2D=type 2 diabetes.

    Reference: 1. Firialta Professional Information; 24 November 2025.